SymBio Pharmaceuticals Limited
SYMQY · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.07 | -0.06 | 0.09 |
| FCF Yield | 0.00% | 0.00% | 0.00% | 0.00% |
| EV / EBITDA | -5.00 | -634.30 | -47.20 | -4.49 |
| Quality | ||||
| ROIC | -29.61% | -26.84% | -28.75% | -25.98% |
| Gross Margin | 62.28% | 76.10% | 76.66% | 77.43% |
| Cash Conversion Ratio | – | – | – | – |
| Growth | ||||
| Revenue 3-Year CAGR | -44.60% | -39.79% | -38.79% | -37.43% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 0.96 | 254.42 | 21.59 | 3.73 |
| Interest Coverage | -40.82 | -2,755.70 | -211.69 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.37 | 0.33 | 0.24 | 0.53 |
| Cash Conversion Cycle | 297.36 | 318.74 | 446.96 | 240.17 |